Cyllene Therapeutics
French tech company | Builders Republic
About
Clinical-stage biotech developing gene therapies for chronic urological and neurological diseases — built on Hermes, a non-replicating herpes (HSV-1) vector platform that delivers genetic medicine to selectively silence overactive sensory nerves, with a lead program targeting overactive and neurogenic bladder.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series C
- Founded
- 2019
- City
- PARIS
- Region
- IDF
- Tracked rounds
- 5
- Amount raised
- 80 M€ raised since 2020
Funding rounds
- Series C · 2026
- Series B · 2025
- Extension · 2023
- Series A · 2021
- Seed · 2019
Investors
- Andera Partners
- Bpifrance Life Sciences Venture
- En Pointe LLC
- GordonMD Global Investments
- Lamond Ventures
- M Ventures
- SCI Ventures
Notes
Anciennement EG 427, la société a été renommée Cyllene Therapeutics en juillet 2026, à l'occasion de sa série C.